Back

Chimerophore antibiotics: engineered multimodal host defense peptides

Armas-Egas, L.; Lagler, S.; Panke, S.; Held, M.

2026-08-06 microbiology
10.64898/2026.08.06.743220 bioRxiv
Show abstract

Ribosomally synthesized host defense peptides (HDPs) are promising candidates for novel antibiotics. However, non-lytic HDPs, which target intracellular machinery, remain underexploited due to limitations including low potency in serum and narrow activity spectra. To enhance their therapeutic profile, we fused non-lytic HDPs generating "chimerophores" with multimodal mechanisms of action (MOAs). Using a high-throughput self-screening platform (Mex), we synthesized and evaluated a combinatorial library of 99,235 variants, identifying over 30,300 active chimerophores, vastly expanding the functional space of chimeric HDPs. Functional screening of 18 chimerophores revealed candidates with potent, broad-spectrum activity displaying serum-tolerance, low cytotoxicity, orthogonal uptake pathways and multimodality, such as simultaneously targeting of ribosomes and DNA. Integrating these distinct mechanisms into a single molecule allowed lead candidate cp9 to suppress the emergence of resistance in Pseudomonas aeruginosa, establishing a scalable platform for the systematic engineering of next-generation multimodal antibiotics.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.